Tiger Brokers

BUZZ-Brokerages turn bullish on Kymera after positive early trial data

Reuters
Jun 03, 2025
BUZZ-Brokerages turn bullish on Kymera after positive early trial data

** Shares of drug developer Kymera Therapeutics KYMR.O rise 3.41% premarket, after gaining ~45% in previous session

** Company said on Monday its experimental oral drug effectively reduced STAT6 levels in blood and skin during an early-stage trial

** The drug, KT-621, is designed to target STAT6, a key signaling protein involved in immune response

** Brokerages, including BofA Global Research and Morgan Stanley, upgrade rating on stock to "buy" equivalent

** "The data increases our confidence in KT-621's ability to compete across large I&I (immunology and inflammation) indications, and in Kymera's platform more broadly" - Morgan Stanley

** All 20 brokerages covering the stock have rating "buy" or higher; median PT is $60 - data compiled by LSEG

** Through Monday, KYMR shares up ~7% so far this year

(Reporting by Joel Jose in Bengaluru)

((mailto: joeljose@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10